News & stories – CEPI

Latest news

Filter by category:

FILTER: ALL CATEGORIESFilter by:

Latest news

Two expert health leaders join CEPI Board

World-leading health experts Dr. Nísia Trindade Lima and Dr. Juan Pablo Uribe have been appointed to the CEPI Board.

Joint COVAX statement on Supply Forecast for 2021 and early 2022

According to its latest Supply Forecast, COVAX expects to have access to 1.425 billion doses of vaccine in 2021.

Comparator vaccines are needed if vital COVID-19 R&D is to progress

Governments, developers, and particularly vaccine manufacturers, must urgently agree upon a solution to unlock supplies, writes CEPI's Director of Vaccine R&D, Melanie Saville.

Zalgen Awarded CEPI Contract to Provide Test Kits for Largest Ever Lassa Fever Study in West Africa

The study, Enable, seeks to better understand the rate, location, and spread of Lassa virus across the region, while also informing the location and implementation of future late-stage trials of Lassa vaccines.

CEPI partners, IVI and BBIL, launch global Chikungunya vaccine Phase II/III trial in Costa Rica

IVI is leading the Global Chikungunya vaccine Clinical Development Program consortium in partnership with Bharat Biotech, and with support from CEPI and Ind-CEPI.

CEPI welcomes US FDA approval of Pfizer/BioNTech’s COVID-19 vaccine

Statement from the CEO of CEPI, Dr. Richard Hatchett.

CEPI enters into funding agreement with Gritstone bio to develop COVID-19 variant vaccine

Programme forms part of CEPI’s efforts to develop “next-generation” COVID-19 vaccines

Efforts to advance Rift Valley fever vaccines progress with new CEPI partnership

Serum material donated from patients recovered from Rift Valley fever will support the development of a reference tool used to assess Rift Valley fever vaccines undergoing clinical trials.

CEPI and Universiti Malaya announce new collaboration to advance Nipah virus research

The research aims to characterize and better understand immune responses generated against the virus - one of the deadliest pathogens known to infect humans.

Largest ever Lassa fever study expands to more countries in West Africa

Up to 23,000 participants will be enrolled into the research programme in Benin, Guinea, Liberia, and Sierra Leone, as well as Nigeria, which began collecting data in December 2020.

CEPI partners with Shanghai Zerun Biotech to develop COVID-19 variant vaccine

CEPI will provide US$13.1 million to advance development of both COVID-19 prototype and variant vaccine candidates.

Twitter

Follow

Tweets by CEPIvaccines

Media enquiries

Get involved in our cause

Become a partner